Brooks Laboratories Limited

Brooks Laboratories Limited

Brooks Laboratories Limited announced the closure of its trading window for Designated Persons and their immediate relatives, effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting and the opening of the trading window will be communicated later.

Brooks Laboratories Limited

Brooks Laboratories Limited announced it received a request from BSE Limited for additional details regarding its previously disclosed "Partial Sale of Equity Shares Held in Brooks Steriscience Limited" on June 19, 2026. The exchange specifically sought the Board Meeting commencement and conclusion times related to that transaction, in compliance with SEBI regulations. The company is submitting a revised disclosure to provide these required details. For investors, this update signifies regulatory scrutiny of the company's significant transaction and Brooks Laboratories' proactive adherence to disclosure norms.

Brooks Laboratories Limited

Brooks Laboratories Limited announced its board has approved the sale of 51,220 equity shares in Brooks Steriscience Limited. The shares will be sold to Steriscience Specialities Private Limited for a cash consideration of ₹20,760 per share. This transaction aggregates to approximately ₹106.33 crore, pending customary documentation and regulatory requirements. For investors, this represents a significant divestment by Brooks Laboratories, generating substantial cash flow which could be used for other strategic initiatives or strengthening its financial position.